 | |
 Headquarters in Basel | |
| Company type | Public |
|---|---|
| ISIN | CH0012005267 |
| Industry | Pharmaceuticals |
| Predecessors |
|
| Founded |
|
| Founders |
|
| Headquarters | Basel, Switzerland (47°34′28″N 7°34′35″E / 47.5744252°N 7.5764914°E) |
Area served | Worldwide |
Key people | |
| Products | Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...) |
| Revenue |  US$45.44 billion (2023) |
| US$9.77 billion (2023) | |
| US$14.85 billion (2023) | |
| Total assets |  US$99.95 billion (2023) |
| Total equity | US$46.75 billion (2023) |
Number of employees | 76,057 (2023) |
| Website | novartis |
| Footnotes / references [1][2][3] | |
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.[4][5]
Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz.[6] It was considered the largest corporate merger in history during that time.[6] The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes” (new skills).[6]
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business. The new company also acquired a series of acquisitions in order to strengthen its core businesses.[6]
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA),[7] the Biotechnology Innovation Organization (BIO),[8] the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),[9] and the Pharmaceutical Research and Manufacturers of America (PhRMA).[10] Novartis is the third most valuable pharmaceutical company in Europe, after Novo Nordisk and Roche.
- ^ "Research Locations". Novartis.
- ^ "Novartis 1Q profit jumps 12 percent as heart drug sales soar". Business. The Seattle Times. Associated Press. 19 April 2018. Archived from the original on 5 August 2020. Retrieved 20 April 2018.
- ^ "Novartis Annual Report 2023" (PDF). Novartis AG. Archived (PDF) from the original on 31 January 2024. Retrieved 1 February 2024.
- ^ "Who are the top 10 pharmaceutical companies in the world (2022)? | Proclinical Blogs". Proclinical. Retrieved 11 July 2023.
- ^ "Top 25 Pharma & BioPharma in 2022 | Contract Pharma". www.contractpharma.com.
- ^ a b c d Mendenhall, Mark E. (2005). Mergers and Acquisitions: Managing Culture and Human Resources. Stanford, CA: Stanford University Press. p. 380. ISBN 0-8047-4661-3.
- ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original (PDF) on 16 September 2008. Retrieved 25 August 2008.
- ^ "BIO Member Directory | BIO". www.bio.org. Retrieved 1 March 2024.
- ^ "IFPMA Member List". Archived from the original on 7 February 2014. Retrieved 29 January 2021.
- ^ "404". www.phrma.org. Archived from the original on 6 October 2013. Retrieved 29 January 2021.
{{cite web}}: Cite uses generic title (help)